CN103127112A - 一类喹啉酮衍生物在肿瘤治疗中的应用 - Google Patents
一类喹啉酮衍生物在肿瘤治疗中的应用 Download PDFInfo
- Publication number
- CN103127112A CN103127112A CN2013100622147A CN201310062214A CN103127112A CN 103127112 A CN103127112 A CN 103127112A CN 2013100622147 A CN2013100622147 A CN 2013100622147A CN 201310062214 A CN201310062214 A CN 201310062214A CN 103127112 A CN103127112 A CN 103127112A
- Authority
- CN
- China
- Prior art keywords
- cancer
- carcinoma
- muc1
- purposes
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100622147A CN103127112A (zh) | 2013-02-27 | 2013-02-27 | 一类喹啉酮衍生物在肿瘤治疗中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100622147A CN103127112A (zh) | 2013-02-27 | 2013-02-27 | 一类喹啉酮衍生物在肿瘤治疗中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103127112A true CN103127112A (zh) | 2013-06-05 |
Family
ID=48487984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100622147A Pending CN103127112A (zh) | 2013-02-27 | 2013-02-27 | 一类喹啉酮衍生物在肿瘤治疗中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103127112A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997044037A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
WO2002002108A1 (en) * | 2000-06-30 | 2002-01-10 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
JP2003146972A (ja) * | 2001-11-14 | 2003-05-21 | Teikoku Hormone Mfg Co Ltd | カルボスチリル誘導体 |
WO2004065379A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | Androgen receptor antagonists |
CN1688547A (zh) * | 2002-07-03 | 2005-10-26 | 韦恩州立大学 | 作为抗肿瘤剂的a-′7-卤代-2-喹(喔)啉氧基苯氧基-丙酸衍生物 |
CN1775759A (zh) * | 1999-08-27 | 2006-05-24 | 利甘德药品公司 | 二环类雄激素和孕甾酮受体调节化合物和方法 |
WO2011060036A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | Bicyclic compounds and methods of use thereof |
-
2013
- 2013-02-27 CN CN2013100622147A patent/CN103127112A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997044037A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CN1775759A (zh) * | 1999-08-27 | 2006-05-24 | 利甘德药品公司 | 二环类雄激素和孕甾酮受体调节化合物和方法 |
WO2002002108A1 (en) * | 2000-06-30 | 2002-01-10 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
JP2003146972A (ja) * | 2001-11-14 | 2003-05-21 | Teikoku Hormone Mfg Co Ltd | カルボスチリル誘導体 |
CN1688547A (zh) * | 2002-07-03 | 2005-10-26 | 韦恩州立大学 | 作为抗肿瘤剂的a-′7-卤代-2-喹(喔)啉氧基苯氧基-丙酸衍生物 |
WO2004065379A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | Androgen receptor antagonists |
WO2011060036A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | Bicyclic compounds and methods of use thereof |
Non-Patent Citations (2)
Title |
---|
NITESH KUMAR等: "Preliminary investigation of cytotoxic potential of 2-quinolone derivatives using in vitro and in vivo (solid tumor and liquid tumor) models of cancer", 《ARABIAN JOURNAL OF CHEMISTRY》 * |
葛海霞等: "2(1H)-喹啉酮类化合物的药理活性及构效关系", 《药学进展》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jia et al. | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction | |
Arbiser et al. | Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis | |
Semenza | Regulation of cancer cell metabolism by hypoxia-inducible factor 1 | |
Wu et al. | Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade | |
Ros et al. | Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2, 6-bisphosphatases in cancer metabolism | |
Matthews et al. | Anti‐tumour/metastasis effects of the potassium‐sparing diuretic amiloride: an orally active anti‐cancer drug waiting for its call‐of‐duty? | |
Boosani et al. | PTEN modulators: a patent review | |
Wu et al. | Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway | |
Sinha et al. | Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis | |
Bhattacharya et al. | Mahanine, a novel mitochondrial complex-III inhibitor induces G0/G1 arrest through redox alteration-mediated DNA damage response and regresses glioblastoma multiforme | |
Aihara et al. | The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma | |
Yang et al. | Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells | |
Liu et al. | MicroRNA-34a suppresses autophagy in tubular epithelial cells in acute kidney injury | |
Li et al. | PKM2 inhibitor shikonin suppresses TPA‐induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells | |
CN104363913A (zh) | Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途 | |
Berridge et al. | Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect | |
Wu et al. | Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study | |
Shirley et al. | Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target | |
Shen et al. | Role of galectin‐1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway | |
Murakami et al. | Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model | |
Choi et al. | Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival | |
Yang et al. | Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro | |
Wang et al. | Down-regulation of FOXR2 inhibits non-small cell lung cancer cell proliferation and invasion through the Wnt/β-catenin signaling pathway | |
Li et al. | PAK as a therapeutic target in gastric cancer | |
Liu et al. | MELK accelerates the progression of colorectal cancer via activating the FAK/Src pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150126 Owner name: NANJING MTC BIOPHARMA TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LIMITED Effective date: 20150126 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150126 Address after: 210042 Xuanwu Avenue, Xuanwu District, Jiangsu, Nanjing 699-18 Applicant after: NANJING BIOSCIKIN LTD. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited Applicant before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130605 |
|
WD01 | Invention patent application deemed withdrawn after publication |